Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

NCT05214183 is registered in ClinicalTrials.gov with Nordic Lymphoma Group as lead sponsor.

NCT NCT05214183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05214183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
Lead sponsor
Nordic Lymphoma Group
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 15, 2021
Completion date
January 31, 2027
Enrollment
81 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma, mcl